Scaling Europe
00:20:15 · Oliver Vince
[00:20:15] S1: I think they are realistically tactical. Right? They're they're... Do you overspend in some... You know, do I I think it will work, and I think if you had infinite money and infinite time, I would be a 100% sure that it's gonna work. The question is whether you... From an a company building standpoint, whether you can do that. And I think, like like, more specifically, right, like, it's kind of... Back to being very, very simple, all you're doing is learning to read DNA and write DNA. And basically, the bigger the model gets, the longer piece it can read with a higher accuracy and the longer it can write with higher accuracy. And so basically, the question is like, how much does... How big does a model need to get to write, you know, 20 letters, 30 letters, 40 letters? And then what can you do with 20 letters, 30 letters, 40 letters? And how valuable is that? Right? So, like, is it... If you need to operate in a world where you need to monetize 20 letters for, like, five years and then monetize 30 letters for five years, you can do it, but it's a very different approach to saying, look, the fact that we've gone from 20 to 30 to 40 shows that we will get there to a 100 or a 150 or a thousand. But, you know, like that requires a bit of a leap of faith, which ultimately is where the tech companies are interesting because they've taken that leap of faith and they've seen it before, which is very, very different in some senses to many of the sort of established ways of developing medicine.
00:21:42 · Sebastian Johnson, Oliver Vince
[00:21:42] S0: Have you faced any cynicism or skepticism from that more traditional industry versus the tech industry? [00:21:50] S1: Of course. Of course we have. Right? And, like, I mean, to be clear, like, I... You know, many of us have... I have background in... My PhD was in cancer research. I have... Like, many of our team have... Are are, like, trying to be realistic and optimistic at the same time. And so we're aware of our own flaws and why this doesn't work better than anybody else. But it really is just like, look, there is a promise there, and therefore, it's worth doing. And you kind of... If you can get people to accept that, it's a very, very, very exciting and very fulfilling thing to do because you're not guaranteeing anyone anything, but you're saying, look, here's the potential. It's unequivocally huge if it works. Now let's go on the ride and see if it works. Right?
00:21:50 · Oliver Vince, Sebastian Johnson
[00:21:50] S1: Of course. Of course we have. Right? And, like, I mean, to be clear, like, I... You know, many of us have... I have background in... My PhD was in cancer research. I have... Like, many of our team have... Are are, like, trying to be realistic and optimistic at the same time. And so we're aware of our own flaws and why this doesn't work better than anybody else. But it really is just like, look, there is a promise there, and therefore, it's worth doing. And you kind of... If you can get people to accept that, it's a very, very, very exciting and very fulfilling thing to do because you're not guaranteeing anyone anything, but you're saying, look, here's the potential. It's unequivocally huge if it works. Now let's go on the ride and see if it works. Right? [00:22:32] S0: Let's take that swing. It's amazing. I love it. This is like... It's it's amazing to hear when, you know, there there are some companies today that are building truly frontier technologies, especially here in London that are really game changing for the world. Right? And, you know, there's a lot of stuff going on, a lot of doomism around AI at the moment. It makes me so happy to see that so many of these great companies that are truly tackling some of the biggest problems in the world, And, like, here in London doing amazing stuff. Well, anyway, thank you so much, Oliver. This is phenomenal news. Huge congratulations, and I look forward to to seeing your your progress and your journey and maybe being You're treated one [00:23:08] S1: very kind. Thank you, my friend.